According to a study in Respirology published by Wiley-Blackwell, treatments with oral Bosentan reduces resistance in blood flow – allowing the heart and lungs to work more efficiently and in turn, enables patients to increase exercise capacity and quality of life.
PAH is a syndrome where one experiences continuous high blood pressure in the pulmonary arteries, or the blood vessels supplying blood to the lungs. In PAH, the heart has to work very hard to pump against the high resistance and eventually weakens. When it loses the ability to pump enough blood, heart failure occurs and often death.
Although there is no cure for PAH, there are treatments that are beneficial to the patients. Bosentan is an oral endothelin receptor antagonist that significantly improves functional status, increase blood flow and survival of patients.
Lead author, Mr. Geoff Strange says, “Quality of life is an important consideration in the treatment of diseases such as PAH, in which prognosis is typically poor. In such chronic diseases, patients view improvement in quality of life as an important measure of treatment success.”
After three months of Bosentan treatment, patients showed improvements in their exercise capacity in the six minute walk test (6MWT), as well as domains that measured quality of life. Although the assessment of quality of life and 6MWT provides complementary data at individual time points, they did not correlate over time as a response to therapy.
Professor Eli Gabbay, from the Royal Perth Hospital and The University of Western Australia adds, “While quality of life and 6MWT data were parallel at individual points, quality of life may improve on Bosentan therapy independent of the improvements in 6MWT. The quality of life domains should be specifically assessed to improve the monitoring of patients with PAH as changes in quality of life cannot be extrapolated from routine clinical variables.”
Alina Boey | alfa
NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases
Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences
For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.
In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...
The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...
At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.
When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...
19.03.2018 | Event News
16.03.2018 | Event News
13.03.2018 | Event News
19.03.2018 | Physics and Astronomy
19.03.2018 | Materials Sciences
19.03.2018 | Event News